CMS looks to adapt ACO benchmarks to regional realities

The Centers for Medicare and Medicaid Services is proposing changes in the benchmarks it uses to evaluate ACOs in the Medicare Shared Savings Program.

In a fact sheet posted Jan. 28, the agency indicates it wants to segue from its initial focus on ACOs’ respective historical-spending benchmarks to the ACOs’ performance controlling fee-for-service costs within their respective regions during a second or subsequent agreement period.

To make the move, CMS would reset participating ACOs’ benchmarks in such a way as to:

  • Establish each ACO’s “rebased” historical benchmark by replacing the current national trend factor with regional trend factors;
  • Adjust the ACO’s rebased historical benchmark to reflect the difference between the regional fee-for-service costs in the ACO’s regional service area and the ACO’s historical expenditures; and
  • Update, on an annual basis, the rebased benchmark to account for changes in regional fee-for-service spending.

The latter change would replace the current update, which is based solely on the absolute amount of projected growth in national fee-for-service spending.

In a press release promoting the action, Andy Slavitt, the agency’s acting administrator, says the changes would facilitate ACO success by having CMS recognize “both their achievements and improvements in how they provide care.”

“This should have the effect of growing the number of ACOs, and making ACOs and the coordinated care they provide to patients, more of a standard in all parts of the country,” Slavitt adds.

CMS says its Jan. 28 proposal reflects extensive input from stakeholders.

The proposed rule will be open for comment for 60 days.

For more information and related links, click here for the fact sheet and here for the press release.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.